Teva inks partnership with Klinge to launch Eylea biosimilar in Europe

Teva Pharmaceutical (NYSE:TEVA) has entered into a strategic collaboration with Klinge Biopharma and Formycon AG, for the semi-exclusive commercialization of FYB203, Formycon’s biosimilar candidate to Eylea in Europe and in Israel, the company said Monday.

This partnership combines Teva’s (TEVA